Multiple BM harvests in pediatric donors for thalassemic siblings: safety, efficacy and ethical issues

Bone Marrow Transplant. 2008 Sep;42(6):379-84. doi: 10.1038/bmt.2008.177. Epub 2008 Jun 23.

Abstract

Allogeneic BMT represents the only chance of cure for beta-thalassemia. Occasionally, two affected individuals from the same family share a matched healthy sibling. Moreover, a high incidence of transplant rejection is still observed in Pesaro class III patients, requiring a second BMT procedure. In these settings, one option is to perform a second BM harvest from the same donor. Although BM harvest is a safe procedure in children, ethical issues concerning this invasive practice still arise. Here, we describe our series of seven pediatric, healthy donors, who donated BM more than once in favor of their beta-thalassemic HLA-identical siblings between June 2005 and January 2008. Three donors donated BM twice to two affected siblings and four donors donated twice for the same sibling following graft rejection of the first BMT. All donors tolerated the procedures well and no relevant side effects occurred. There was no significant difference between the two harvests concerning cell yield and time to engraftment. Our experience shows that for pediatric donors, a second BM donation is safe and feasible and good cellularity can be obtained. We suggest that a second harvest of a pediatric donor can be performed when a strong indication for BMT exists.

MeSH terms

  • Adolescent
  • Bioethical Issues*
  • Bone Marrow Transplantation / ethics*
  • Bone Marrow*
  • Child
  • Child, Preschool
  • Donor Selection / ethics*
  • Donor Selection / methods
  • Female
  • HLA Antigens
  • Humans
  • Living Donors / ethics*
  • Male
  • Retrospective Studies
  • Safety*
  • Siblings
  • Transplantation, Homologous
  • beta-Thalassemia / therapy*

Substances

  • HLA Antigens